低浓度对比剂、低辐射剂量联合迭代重建的双源ct冠状动脉成像临床应用

《低浓度对比剂、低辐射剂量联合迭代重建的双源ct冠状动脉成像临床应用》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、分类号R445第四军医大学UDC616TheFourthMilitaryMedicalUniversity密级公开硕士学位论文低浓度对比剂、低辐射剂量联合迭代重建的双源CT冠状动脉成像临床应用武永杰培养类别全日制学位类型专业学位一级学科(专业类)临床医学二级学科(专业)影像医学与核医学研究方向心血管CT低剂量研究指导教师郑敏文副教授（副主任医师）培养单位西京医院放射科二O一五年五月第四军医大学硕士学位论文目录缩略语表···································································

2、··································1中文摘要·····································································································2英文摘要·····································································································5前言与文献回顾·······················

3、····································································9正文····································································································22第一部分低浓度对比剂、低辐射剂量联合迭代重建算法的CCTA前门控成像研究··221材料与方法··························································

4、······························231.1患者资料······················································································231.2检查设备与方法············································································231.3图像重建·······················································

5、·······························241.4冠状动脉近段及其它心血管解剖部位的图像噪声、对比增强···············241.5主观图像质量和有效辐射剂量·························································241.6对比剂不良反应观察······································································251.7统计学分析·······························

6、····················································252结果·································································································252.1一般资料和扫描参数······································································252.2冠状动脉对比增强CT值·······················

7、········································252.3其它心血管解剖部位的图像噪声、对比增强CT值····························282.4主观图像质量和辐射剂量·······························································282.5对比剂不良反应············································································283讨论··········

8、·····························································